Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. Undoubtedly, this has played a factor in the success of market-leading PD-1 inhibitors, Merck & Co.’s Undoubtedly, this has played a factor in the success of market-leading PD-1 inhibitors, Merck & Co.’s

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130

Antibody DNA Development Vaccination 130

pharmaphorum

OCTOBER 29, 2021

Hopefully a new standard of care for the aggressive disease, according to partners Gilead Sciences and Merck & Co. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. COVID-19 therapy Veklury (remdesivir) continued to lead the charge at Gilead with a massive $1.9

Trials 52

Trials Sales FDA Approval Production 52

pharmaphorum

APRIL 5, 2022

The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.

Protein 52

Protein Sales Drugs Trials 52

pharmaphorum

JANUARY 5, 2021

First-line immunotherapy for NSCLC is dominated by Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab), transforming the prospects of some patients and propelling the drug to multibillion-dollar sales. Meanwhile, drugs targeting TIM-3, LAG3, VISTA and STING also coming through development.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. There are several different types of immunotherapies, including chemical inhibitors, cell-based therapies (i.e. chimeric receptor antigen [CAR] T cell) immune modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98